Kurt Schalper
Overview
Explore the profile of Kurt Schalper including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
1976
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Skoulidis F, Araujo H, Do M, Qian Y, Sun X, Cobo A, et al.
Nature
. 2025 Feb;
639(8054):E19.
PMID: 40016449
No abstract available.
2.
Chou T, Dacic S, Wistuba I, Beasley M, Berezowska S, Chang Y, et al.
J Thorac Oncol
. 2024 Nov;
20(3):311-330.
PMID: 39579981
Introduction: With the implementation of low-dose computed tomography screening, multiple pulmonary tumor nodules are diagnosed with increasing frequency and the selection of surgical treatments versus systemic therapies has become challenging...
3.
Skoulidis F, Araujo H, Do M, Qian Y, Sun X, Cobo A, et al.
Nature
. 2024 Oct;
635(8038):462-471.
PMID: 39385035
For patients with advanced non-small-cell lung cancer (NSCLC), dual immune checkpoint blockade (ICB) with CTLA4 inhibitors and PD-1 or PD-L1 inhibitors (hereafter, PD-(L)1 inhibitors) is associated with higher rates of...
4.
Riess J, Lara M, Lopez de Rodas M, Luxardi G, Herbert S, Shimoda M, et al.
JTO Clin Res Rep
. 2024 Sep;
5(10):100706.
PMID: 39318388
Introduction: EGFR-mutated NSCLC is minimally responsive to programmed cell death protein 1 or programmed death-ligand 1 blockade. We evaluated the safety, tolerability, and immunomodulatory effects of the EGFR tyrosine kinase...
5.
Shimonov S, Cunningham J, Talmon R, Aizenbud L, Desai S, Rimm D, et al.
bioRxiv
. 2024 Jan;
PMID: 38260586
Spatially resolved transcriptomics or proteomics data have the potential to contribute fundamental insights into the mechanisms underlying physiologic and pathological processes. However, analysis of these data capable of relating spatial...
6.
Biswas S, Kang K, Ng K, Radivoyevitch T, Schalper K, Zhang H, et al.
Cell Rep
. 2023 Aug;
42(8):113016.
PMID: 37597186
Small cell lung cancers (SCLCs) rapidly resist cytotoxic chemotherapy and immune checkpoint inhibitor (ICI) treatments. New, non-cross-resistant therapies are thus needed. SCLC cells are committed into neuroendocrine lineage then maturation...
7.
Barrera C, Corredor G, Viswanathan V, Ding R, Toro P, Fu P, et al.
NPJ Precis Oncol
. 2023 Jun;
7(1):52.
PMID: 37264091
The tumor immune composition influences prognosis and treatment sensitivity in lung cancer. The presence of effective adaptive immune responses is associated with increased clinical benefit after immune checkpoint blockers. Conversely,...
8.
Mino-Kenudson M, Schalper K, Cooper W, Dacic S, Hirsch F, Jain D, et al.
J Thorac Oncol
. 2022 Oct;
17(12):1335-1354.
PMID: 36184066
Immunotherapy including immune checkpoint inhibitors (ICIs) has become the backbone of treatment for most lung cancers with advanced or metastatic disease. In addition, they have increasingly been used for early...
9.
Ding R, Prasanna P, Corredor G, Barrera C, Zens P, Lu C, et al.
NPJ Precis Oncol
. 2022 Jun;
6(1):33.
PMID: 35661148
Despite known histological, biological, and clinical differences between lung adenocarcinoma (LUAD) and squamous cell carcinoma (LUSC), relatively little is known about the spatial differences in their corresponding immune contextures. Our...
10.
Khunger M, Hernandez A, Pasupuleti V, Rakshit S, Pennell N, Stevenson J, et al.
JCO Precis Oncol
. 2022 Feb;
1:1-15.
PMID: 35172490
Purpose: Drugs targeting the programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) pathway show significant clinical activity across several tumor types. However, a majority of patients do not...